secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-016989
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC
---------------------------------------------------------------------------

- First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.
- 44 active international sites across Europe/Asia; trial evaluates ateganosine as 3L NSCLC therapy.
- $2.3M NIH grant funds third-line evaluation; holds FDA Fast Track designation.
- 2025 data: eight patients with overall survival beyond 2 years, four over 30 months, one at 33 months.
- Approximately 50,000 advanced NSCLC patients in U.S. annually progress to third-line treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/0001493152-26-016989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer